BDWM
BTAI icon

Brewin Dolphin Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-125
Closed -$86.3K – 340
2021
Q1 		$86.3K Buy
+125
New +$101K 0.01% 148

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Brewin Dolphin Wealth Management's BTAI Position: Q2 2021 in Review

Brewin Dolphin Wealth Management sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 125 shares — an estimated $86.3K sold.

Brewin Dolphin Wealth Management first reported a position in BTAI in Q1 2021 and held it in 1 quarter. The position peaked at $86.3K in Q1 2021. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Brewin Dolphin Wealth Management reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Brewin Dolphin Wealth Management sold 125 BioXcel Therapeutics shares in Q2 2021, an estimated $86.3K.
  • Brewin Dolphin Wealth Management first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 1 quarter.
  • Brewin Dolphin Wealth Management's BioXcel Therapeutics position peaked at $86.3K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2021, filed 9 Nov 2023.